Form 4: Former Director's Share Conversion Post-Merger
Statement of Changes in Beneficial Ownership
A former director of Helix Acquisition Corp. II converted 30,000 shares into BridgeBio Oncology Therapeutics common stock following a business combination and domestication.
Summary
- Mark C. McKenna, a former director of Helix Acquisition Corp. II, reported changes in beneficial ownership.
- The changes occurred on August 11, 2025, in connection with the business combination between Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics, Inc.) and TheRas, Inc.
- 30,000 Class B ordinary shares of Helix were converted into 30,000 Class A ordinary shares of Helix on a one-for-one basis.
- Following the domestication of Helix into a Delaware corporation, these 30,000 Class A ordinary shares were converted into 30,000 shares of BridgeBio Oncology Therapeutics, Inc. common stock, also on a one-for-one basis.
- McKenna resigned from his director role at Helix effective August 11, 2025, immediately prior to the domestication.
- The reporting person beneficially owns 30,000 shares of common stock after these transactions.
Sentiment
Score: 5
Explanation: The filing is a routine Form 4 reporting a technical share conversion and director resignation related to a corporate business combination and domestication, indicating no immediate positive or negative operational or financial news.
Positives
- Successful completion of the business combination between Helix Acquisition Corp. II and TheRas, Inc., leading to the formation of BridgeBio Oncology Therapeutics, Inc.
Negatives
- Resignation of Mark C. McKenna as a director of Helix Acquisition Corp. II effective August 11, 2025, immediately prior to the domestication.
Future Outlook
NA
Industry Context
NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Mark C. McKenna | NA | 08/11/2025 | Resigned immediately prior to the domestication of Helix Acquisition Corp. II into BridgeBio Oncology Therapeutics, Inc. and the closing of the business combination with TheRas, Inc. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Domestication | Helix Acquisition Corp. II migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised). | 08/11/2025 | This change affects the legal domicile and corporate structure of the entity, aligning it with U.S. corporate law for the newly formed BridgeBio Oncology Therapeutics, Inc. |
Stakeholder Impact
- Shareholders: Existing shareholders of Helix Acquisition Corp. II had their shares converted into common stock of BridgeBio Oncology Therapeutics, Inc. as part of the business combination.
Key Dates
| Date | Description |
|---|---|
| 08/11/2025 | Date of earliest transaction; effective date of Mark C. McKenna's resignation as director of Helix; date of domestication and share conversion. |
Recommendation
holdThis Form 4 filing details a technical share conversion and a director's resignation following a business combination and domestication. It provides no new operational or financial information that would warrant a change in investment thesis. The transaction is a procedural outcome of a previously announced corporate event, thus a 'hold' recommendation is appropriate as there's no new catalyst for significant price movement based solely on this filing.
Keywords
BridgeBio Oncology Therapeutics, BBOT, Helix Acquisition Corp. II, TheRas Inc., Form 4, beneficial ownership, share conversion, domestication, business combination, director resignation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.